FDA clears Siemens' Somatom CT for lung cancer screening

Siemens Healthcare has received clearance from the U.S. Food and Drug Administration (FDA) for its Somatom CT systems for low-dose lung cancer screening.

The indication for low-dose lung cancer screening is available for the following CT systems: Somatom Force, Somatom Definition Flash, Somatom Definition Edge, Somatom Definition AS/AS+, Somatom Perspective, Somatom Scope, and the Somatom Emotion 16.

With its Fully Assisting Scanner Technologies (FAST) features, Siemens optimizes CT acquisition by reducing user variability so technologists can set an optimum range for scan settings that avoids cutoffs or excessive radiation. And with its Combined Applications to Reduce Exposure (CARE) feature, Siemens delivers an approach to optimizing radiation dose in scan parameters that supports efficient clinical workflow, the firm said. Other features in the Somatom portfolio also aid the radiologist in reporting dose and sharing findings within the interdisciplinary lung cancer team.